The Drug-Induced Respiratory Disease Website and App

Corticosteroids, systemic (oral, parenteral)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.v

Hypertrophic cardiomyopathy

Publications

Röhr SB, Sauer H, Gottschling S, Abdul-Khaliq H, Gortner L, Nunold H, Gräber S, Meyer S

Non-neurological, steroid-related adverse events in very low birth weight infants: a prospective audit.

Swiss medical weekly. 2014;144:w13954

Bassareo PP, Abella R, Fanos V, Mercuro G

Biomarkers of corticosteroid-induced hypertrophic cardiomyopathy in preterm babies.

Frontiers in bioscience (Elite edition). 2010;2(4):1460-71

Vimala J, Prabhu A, Pavithran S, Kumar RN

Hydrocortisone induced hypertrophic cardiomyopathy.

International journal of cardiology. 2011;150(3):e94-5

Boeuf B, Maragnes P, Belzic I, Lacotte J, Bonte JB, Guillois B

[Glucocorticoid-induced hypertrophic cardiomyopathy in premature infants: apropos of 4 cases].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 1997;4(2):152-7

Gill AW, Warner G, Bull L

Iatrogenic neonatal hypertrophic cardiomyopathy.

Pediatric cardiology. 1996;17(5):335-9